Press Releases August 3, 2026 04:15 PM

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

Seer, Inc. to Present at Canaccord Genuity 46th Annual Growth Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
SEER

Seer, Inc., a proteomics technology company, announced its participation in the Canaccord Genuity 46th Annual Growth Conference, where its management will present company developments and strategy. The presentation will be webcast live and available for replay on Seer's investor website.

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
SEER
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Seer is scheduled to present at a prominent growth conference, highlighting its proteomics technology advancements.
  • The company emphasizes its proprietary Proteograph Product Suite for deep, unbiased proteomic insights.
  • Seer's products are currently intended for research use only, not diagnostic purposes.

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA.

Seer’s management is scheduled to present on Wednesday, August 12th from 8:00 a.m. to 8:25 a.m. Eastern Time / 5:00 a.m. to 5:25 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer's Proteograph Product Suite integrates proprietary engineered nanoparticles, automation instrumentation, optimized consumables, and advanced analytical software. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

Media Contact:
Patrick Schmidt
[email protected] 

Investor Contact:
Marissa Bych
[email protected] 


Risks

  • The company's proteomics products are research-use only, which may limit immediate commercial revenue opportunities.
  • Market reception to the conference presentation may be muted if no new significant product or financial updates are announced.
  • Potential competitive pressures in the biotechnology and proteomics sectors could impact Seer's growth prospects.

More from Press Releases

Apollo Funds Acquire Maverick Water Group Aug 3, 2026 Dorchester Minerals, L.P. Announces Acquisition of Mineral and Royalty Interests Aug 3, 2026 Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Aug 3, 2026 CVG Reports Second Quarter 2026 Results Aug 3, 2026 Cabot Corporation Reports Third Quarter Fiscal Year 2026 Results Aug 3, 2026